| Literature DB >> 25757062 |
Peter J Kerr1, June Liu2, Isabella Cattadori3, Elodie Ghedin4, Andrew F Read5, Edward C Holmes6.
Abstract
Myxoma virus (MYXV) is the type species of the Leporipoxviruses, a genus of Chordopoxvirinae, double stranded DNA viruses, whose members infect leporids and squirrels, inducing cutaneous fibromas from which virus is mechanically transmitted by biting arthropods. However, in the European rabbit (Oryctolagus cuniculus), MYXV causes the lethal disease myxomatosis. The release of MYXV as a biological control for the wild European rabbit population in Australia, initiated one of the great experiments in evolution. The subsequent coevolution of MYXV and rabbits is a classic example of natural selection acting on virulence as a pathogen adapts to a novel host species. Slightly attenuated mutants of the progenitor virus were more readily transmitted by the mosquito vector because the infected rabbit survived longer, while highly attenuated viruses could be controlled by the rabbit immune response. As a consequence, moderately attenuated viruses came to dominate. This evolution of the virus was accompanied by selection for genetic resistance in the wild rabbit population, which may have created an ongoing co-evolutionary dynamic between resistance and virulence for efficient transmission. This natural experiment was repeated on a continental scale with the release of a separate strain of MYXV in France and its subsequent spread throughout Europe. The selection of attenuated strains of virus and resistant rabbits mirrored the experience in Australia in a very different environment, albeit with somewhat different rates. Genome sequencing of the progenitor virus and the early radiation, as well as those from the 1990s in Australia and Europe, has shown that although MYXV evolved at high rates there was no conserved route to attenuation or back to virulence. In contrast, it seems that these relatively large viral genomes have the flexibility for multiple pathways that converge on a similar phenotype.Entities:
Mesh:
Year: 2015 PMID: 25757062 PMCID: PMC4379559 DOI: 10.3390/v7031020
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
The leporipoxviruses.
| Virus | Natural Host | Disease Caused in Natural Host | Geographic Distribution of Natural Host |
|---|---|---|---|
| Myxoma virus | Cutaneous fibroma | South & Central America | |
| Californian Myxoma virus | Cutaneous fibroma | West coast USA & Mexico | |
| Rabbit (Shope) fibroma virus | Cutaneous fibroma | Eastern & central North America to Central and South America | |
| Squirrel fibroma virus | Cutaneous epitheliofibroma; may be generalized and involve internal organs | Eastern North America; introduced in Europe and Britain | |
| Hare fibroma virus | Cutaneous fibroma | Europe but widely introduced to other countries | |
| Western squirrel fibroma virus | Cutaneous thickening | West coast of North America |
1 Woodchucks (Marmota monax) are also susceptible to experimental infection [10,11]; 2 Lepus californicus (Californian jack rabbit) was susceptible experimentally [12]; poxvirus lesions have also been described in Lepus capensis (Cape hare) in Kenya [13] but no virus characterization was done.
Genes in myxoma virus encoding demonstrated or potential immunomodulatory or host-range proteins.
| Gene | Protein Function (no. of Amino Acids; Transcription Time: E [Early], L [Late]) | Reference | Effect on Virulence of Gene Disruption |
|---|---|---|---|
| chemokine binding (260; E) | [ | Generalized myxomatosis; 1/6 survived | |
| TNF binding; antiapoptosis (326; E) | [ | Moderate to severe myxomatosis; 5/8 animals survived | |
| VACV 1 B15 orthologue; Bcl-2 fold (151; E) | [ | Not determined | |
| RDEL motif; antiapoptosis (237; E) | [ | Small rapidly resolved primary lesions; 1/8 rabbits had a secondary; all animals recovered | |
| Antiapoptosis; E3 Ub ligase(483; E) | [ | Primary lesion only; rapid resolution; no signs of clinical myxomatosis | |
| BTB/kelch domains; putative E3 Ub ligase (509; E) | [ | Not determined | |
| Secreted IFN- γ binding protein; chemokine binding (263; E) | [ | 12/13 rabbits mild to moderate disease; lymphocyte infiltration | |
| BTB/kelch domains; putative E3 Ub ligase (515; E) | [ | Not determined | |
| Serp 1; secreted serine proteinase inhibitor (369; L) | [ | Moderate to severe generalized myxomatosis; 5/8 rabbits recovered from infection; enhanced inflammatory response | |
| BTB/kelch domains; putative E3 Ub ligase (509; E) | [ | Not determined | |
| Epidermal growth factor homologue (85; E) | [ | Generalized myxomatosis; 75% of animals recovered | |
| Antiapoptotic factor (166; E) | [ | All rabbits survived; large protuberant demarcated primary; large secondaries; mild conjunctivitis/rhinitis | |
| Pyrin domain inflammasome (126; E) | [ | Mild clinical signs rapidly resolved; small secondaries; no mortality; rapid inflammatory response | |
| BTB/kelch domains; putative E3 Ub ligase (517; E) | [ | Not determined | |
| Type I interferon resistance/PKR inhibition; RNA helicase A binding (115; E) | [ | Abortive infection | |
| VACV O1 orthologue; ERK1/2 signal enhancement (680; E) | [ | Not determined | |
| Host range (158;E/L ) | [ | abortive infection in rabbits and rabbit cells | |
| Host range (215; E) | [ | No virus replication in rabbits and rabbit cells | |
| Virion component (203; E/L) | [ | Slower progression of disease but lethal in rabbits | |
| potential immunomodulatory (53; L) | [ | Not determined | |
| NK cell receptor homologue (176; E) | [ | Not determined | |
| NK cell receptor homologue (172; L) | [ | Not determined | |
| CD47 homologue; macrophage inhibition (281; L) | [ | Mild generalized disease; rapid resolution; no deaths | |
| Unknown function; localized to ER/Golgi, glycosylated but not secreted (122; L) | [ | Generalized myxomatosis but no deaths | |
| Superoxide dismutase inhibition (163; L) | [ | All animals euthanized days 10-11; RFV is attenuated | |
| Immunomodulatory (178; E) | [ | Mild disease with little generalization; all survived | |
| Homology to VACV A52; Bcl-2 fold (179; L?) | [ | Not determined | |
| Sialyltransferase (290; E) | [ | Severe fatal myxomatosis; survival time prolonged | |
| Homology to VACV A52; Bcl-2 fold (188; E) | [ | Not determined | |
| BTB/kelch domains; putative E3 Ub ligase (553; E?) | [ | Not determined | |
| OX-2 homologue (218; E) | [ | Mild generalized disease, rapid resolution, all survived; increased macrophage and T cell activation | |
| RING-E3 Ub ligase; possible apoptosis regulator (234; L) | [ | Not determined | |
| VACV N1 orthologue;TLR signal inhibition; Bcl-2 fold antiapoptosis (108; E?) | [ | Not determined | |
| Ankyrin repeat; putative E3 Ub ligase (675; L) | [ | Moderate generalized; 2/5 rabbits euthanized at 21 days; mononuclear inflammatory response | |
| Ankyrin repeat; putative E3 Ub ligase (490; E/L?) | [ | Moderate generalized with delayed secondaries; 5/5 rabbits survived | |
| NF-κB inhibition; E3 Ub ligase (494; E) | [ | Rapid inflammatory response at primary site; few small secondaries; no respiratory disease; 12/12 recovered by d21 | |
| Serp 2 (333; E) | [ | Primary lesion but few or no secondary lesions; 7/10 recovered | |
| Serp 3 (266; L) | [ | 4/10 infected rabbits recovered; 6/10 euthanized because of respiratory disease; no secondary lesions | |
| MHC downreg; E3 Ub ligase (206; E) | [ | Generalized myxomatosis; 4/12 rabbits euthanized day 14, the remainder recovered | |
| Downregulation of NFκB? Vac M2 orthologue (214; E) | [ | Not determined | |
| interferon resistance; eIF2α homologue (102; L/E?) | [ | Not determined |
1 VACV—vaccinia virus.
Genes missing or substantially modified in RFV compared to Lu.
| Lu Gene | Function | RFV Compared to Lu [ |
|---|---|---|
| Unknown | Missing from RFV | |
| Secreted serine proteinase inhibitor (Serp 1) | Fragmented in RFV | |
| Unknown | 35 aa in RFV; 61 aa in MYXV | |
| unknown | N-terminal truncation | |
| Unknown | 78 aa in RFV; 136 aa in MYXV | |
| Immunomodulatory | Fragmented in RFV | |
| Possible immunomodulatory | Fragmented in RFV | |
| Possible immunomodulatory | Fragmented in RFV | |
| NFκB signal inhibition | Fragmented in RFV | |
| Serp 3 | Fragmented in RFV | |
| eIF2α homologue (IFN resistance) | Truncated N-terminus; duplicated in RFV |
Genes missing or substantially modified in MSW compared to Lu.
| Lu Gene | Function | MSW Compared to Lu [ |
|---|---|---|
| Unknown | ATG but no ORF in MSW | |
| Secreted serine proteinase inhibitor (Serp 1) | Multiple stop codons in MSW | |
| BTB/kelch domains; potential E3 Ub ligase | Loss of 845 nts and multiple indels in MSW | |
| Unknown | Mutation of ATG and disruption of ORF in MSW | |
| Assembly complex | 23 aa extra at N-terminus in MSW | |
| Unknown | N-terminal truncation in MSW | |
| Superoxide dismutase homologue | Multiple stop codons in MSW | |
| Serp 3 | Multiple stop codons in MSW | |
| eIF2α homologue (IFN resistance) | Truncated N-terminus; gene duplicated in MSW |
Virulence grades of MYXV.
| Virulence Grade | Case Fatality Rate (%) | Average Survival Time (Days) 1 |
|---|---|---|
| 1 | 99.5 | ≤13 |
| 2 | 95–99 | 14–16 |
| 3A | 90–95 | 17–22 |
| 3B | 70–90 | 23–29 |
| 4 | 50–70 | 29–50 |
| 5 | <50 | Not determined |
1 Average survival time was calculated by transforming survival times using log10(ST-8) and then back-transformed. This was adjusted to allow for survivors either by the method of Sampford (1954) [136] or by allocating survivors a survival time of 60 days [16,135].
Figure 1Virulence of Myxoma virus isolates in Australia 1952–1981. The proportion of MYXV isolates in each virulence grade (Table 5) is shown. Numbers above the bars indicate the number of isolates tested for each period. Grade 3A and 3B viruses are combined as grade 3. Data are from [137]. Figure is reprinted from Antiviral Research [64] (with permission from Elsevier).
Figure 2Mosquito transmissibility of Myxoma virus. The percentage of mosquitoes that successfully transmitted virus following feeding on cutaneous lesions of rabbits infected with grade 1, grade 4 or grade 5 viruses is shown. Data are from [134]. Figure is reprinted from Antiviral Research [64] (with permission from Elsevier).
Figure 3Transmission of MYXV by fleas 8-28 days after infection with viruses of different virulence grades. Fleas were combed from rabbits infected with viruses of virulence grade 1, 3A, 3B or 5, and tested for transmission by feeding on an uninfected rabbit. Rabbits have been grouped by survival time irrespective of the virus with which they were infected. The average percentage of infective fleas between days 8 and 28 after infection is shown for each group. Data are from [160].
Figure 4Virulence of Myxoma virus isolates in the United Kingdom. The proportion of MYXV isolates in each virulence grade for viruses isolated in the United Kingdom is shown. Numbers above the bars indicate the number of isolates tested. Data are from [171,172].
Figure 5Phylogenetics and phylogeography of Myxoma virus in Australia and Europe. Samples are colour-coded according to location of sampling in the Canberra district of Australia (BRK, green; OB, pink; SWH, red; WS, blue; the state or region of sample collection is indicated in parentheses (ACT, Australian Capital Territory; CD, Canberra district; NSW, New South Wales; QLD, Queensland; TA, Tasmania; VIC, Victoria). Previously determined virulence grades are indicated as 1 to 5. Bootstrap values are shown for key nodes, and all horizontal branches are drawn according to the number of nucleotide substitutions per year. Credible intervals for divergence times for two key nodes are also shown (see [190,195] for details).
Indels disrupting coding regions of MYXV isolates from Australia and Britain [62].
| Gene | Function (Protein Size aa) | Mutation | Effect | Virus (Virulence Grade if Determined) |
|---|---|---|---|---|
| Undetermined (72) | G del | Frameshift from aa 58 and readthrough stop codon adds 5 aa at C terminus | BD44 | |
| apoptosis inhibition/host range (483) | C insert (homopol) | Frameshift from aa 284 stop after aa 317; loss of C-terminal F box | WS6 346 | |
| apoptosis inhibition/host range (483) | C insert | Frameshift; stop after aa 73 | Ur (5) | |
| Secreted Serpin (369) | CC insert (homopol) | Stop after aa 299; loss of active site | BD44 | |
| BTB/kelch domains; putative Ub ligase (509) | A del (homopol) | Additional indel in disrupted ORF | SWH 8/2/93 | |
| BTB/kelch domains; putative Ub ligase (509) | TA insert | Additional indel in disrupted ORF | BRK (1) | |
| BTB/kelch domains; putative Ub ligase (509) | A insert (homopol) | Early stop at aa 146—loss of all kelch domains | All recent Australian except Bendigo (1) | |
| BTB/kelch domains; putative Ub ligase (509) | A del | Early stop at aa 114; additional indel in disrupted ORF | WS6 1071; OB31120 | |
| dUTPpyrophosphatase (148) | 13 nt deletion | Stop after aa 70 | OB3Y317 | |
| BTB/kelch domains; putative Ub ligase (517) | G insert (homopol) | Early stop at aa 477—loss of last kelch domain | Glenfield (1); KM13 (3); Ur (5) | |
| cytoplasmic protein; VACV 1 F8 orthologue (66) | TT insert | Frameshift from aa 60; readthrough adds 20 aa at C-terminus | OB3Y317 | |
| VACV O1 orthologue (680) | 92 nt del | Stop after aa 212 | BRK (1) | |
| VACV O1 orthologue (680) | T insert | Stop after aa 442 | Sussex (3); Nottingham (5) | |
| Thymidine kinase (178) | T insert (homopol) | Readthrough adds LKY to C-terminus | WS1 234 | |
| Carbonic anhydrase homologue/structural (286) | G insert (homopol) | Corrects G deletion in SLS; restores ORF | All recent Australian | |
| Undetermined/virulence (122) | G insert (homopol) | Stop after aa 15 | Glenfield (1) | |
| Transmembrane protein (2000) | A insert (homopol) | Stop at aa 1953; retains predicted C-terminal transmembrane domain | Ur (5); Nottingham (5) | |
| S/T protein kinase (288) | GT del (rpt seq) | Stop after aa 134 | BD23 | |
| NF-κB inhibition (494) | TG insert | Stop after aa 196 | Nottingham (5) | |
| Serp 3 (266/273) | A del (homopol) | Stop after aa 271 | WS6 1071; OB31120 | |
| Ub ligase/MHC-1 downregulation (206) | G del (homopol) | stop after aa 118 | Glenfield (1) | |
| Ub ligase/MHC-1 downregulation (206) | G insert (homopol) | Stop after aa 124 | BD44 | |
| Ub ligase/MHC-1 downregulation (206) | T del | stop after aa 161 | WS6 1071; OB31120 | |
| Ub ligase/MHC-1 downregulation (206) | 73 nt del | Sequence read through replaces C-terminal CR domain of M153 | Meby (5) | |
| eIF2α homologue; IFN resistance (102) | T del | Read through stop—extra EG at C-terminus | WS6 346; OB3Y317 |
1 VACV—vaccinia virus.